NCT04289909Completed
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes occurring along the optic nerve of the brain parenchyma. Indeed, our team has been able to develop a quantitative method to measure the perivascular infiltrate in the retina of patients with various inflammatory retinal disease. It has been observed in MS patients that this perivascular infiltrate can also be detected in the retina. However, its distribution across MS phenotypes (relapsing or progressive MS, with and without optic neuritis) is still unknown.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 25 Feb 2020
- Start date
- Dec 2020
- Primary completion date
- Jun 2024
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Diseases
- Multiple sclerosis
- NCT number
- NCT04289909
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From Dec 2020 to the primary completion date, Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Corticosteroid treatment within one month from inclusion
Other illness
- Other neurological, ophthalmologic or systemic disease;
- Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion)
- Neurological, ophthalmologic or systemic disease;
- Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion);
Lab values
- Severe renal dysfunction (glomerular filtration rate \< 30mL/min). This non-inclusion criteria will be verified by serum creatinine test within six months from inclusion;
Other
- For all patients (Group 1; 2; 3):
- Contraindication for MRI;
- Pregnancy or breast-feeding;
- Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly)
- Incapacity to understand or sign the consent form;
- Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.
- For healthy subjects (Group 4):
- Contraindication for MRI;
- Pregnancy or breast-feeding;
- Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly)
- Incapacity to understand or sign the consent form;
- Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.
Who the study is looking for
- Group 1:
- Age between 18 and 60 years old.
- Relapsing remitting MS (criteria of McDonald 2017)
- Less than 10 years of disease duration
- Subject who has never presented a clinical episode of optic neuritis
- Affiliation to a social security scheme or beneficiary of such a scheme
- Group 2:
- Age between 18 and 60 years old
- Relapsing remitting MS (criteria of McDonald 2017)
- Less than 10 years of disease duration
- Subject presenting an acute episode of retrobulbar optic neuritis within 3 months from onset
- After optimal treatment for the retrobulbar optic neuritis
- Affiliation to a social security scheme or beneficiary of such a scheme
- Group 3:
- Age between 18 and 60 years old
- Primary or Secondary progressive multiple sclerosis within 10 years of progressive phase;
- Affiliation to a social security scheme or beneficiary of such a scheme
- Group 4 (Healthy Subjects):
- Age between 18 and 60 years old
- Affiliation to a social security scheme or beneficiary of such a scheme
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut du Cerveau et de la Moelle epiniere - Hopital Pitie Salpetriere Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.